Validation of exercise effects in patients with Parkinson disease.

Validation of neuroprotective factors reflecting exercise effects in patients with Parkinson disease.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1030220416

Enrollment

120

Registered

2022-10-27

Start date

2022-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

We will destribute activity tracker (acti graph) to recruited and randomized patients with Parkinson disease. Group of exercise

DVD exercise (about 30minutes) and 20 minutes walking at least 5 times/ a week. Group of no exercise / sedentary

Usual daily living activity. We will measure activity 1month (+/-2 weeks) before as a baseline and 1,3,6,9 month after starting exercise. We will keep the score of clinical evaluation, collect patient

D015444, D016138,D009043

exercise, walking, activity

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient (Hoehn and Yahr I,II) with diagnosis of Parkinson disease according to the 2015 MDS (International Parkinson and Movement Disorder Society) crinical diagnostic criteria of Parkinson disease. 2. Able to come to Juntendo University Koshigaya hospital regularly during the study period. 3. Older than 40 years old and yonger than 80 years old with no dementia criteria of a MMSE at a baseline >= 26.

Exclusion criteria

Exclusion criteria: 1.Yonger than 39 years old and older than 81 years old. 2.Patient with diagnosis of cerebrovascular disease, neuroimmunological disease, seizure disorder and neurodegenerative disease, such multiple system atrophy, progressive supranuclear pulsy and Alzheimer disease. 3.Patient with an abnormal ECG or past medical history of coronary infarction. Patient with an obvious orthostatic hypotension. 4.Patient with a hepatic disorder, a renal disorder and malignancy. 5.Others that investigators judged inappropriate.

Design outcomes

Primary

Measure	Time frame
Protein and mRNA amount of mitochondrial protein deacetylase SIRT3 in blood samples of randomly assigned patients in exercise and no exercise group.	—

Secondary

Measure	Time frame
Clinical evaluation; MDS-UPDRS part 3 (movement function scale), MMSE (dementia scale), HAMD (depression scale), non-motor symptoms assessment scale (NMSS). Candidate neuroprotective factors; anti-alpha synuclein antibody, Brain-derived neurotrophic factor (BDNF), Vascular endothelial growth factor (VEGF), DNA methylase 1 (Dnmt1), alpha-synuclein DNA methylation rate.	—

Contacts

Public ContactMaya Ando

Juntendo University Koshigaya Hospital

my-ando@juntendo.ac.jp+81-48-975-0321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026